Pro­tag­o­nist aborts lead ul­cer­a­tive col­i­tis pro­gram af­ter drug fiz­zles in PhI­Ib, stock craters

The lead ther­a­py at Pro­tag­o­nist has flunked a mid-stage tri­al, push­ing the Newark-based com­pa­ny to pull the plug on its ul­cer­a­tive col­i­tis drug PTG-100. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.